ATE454455T1 - Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung - Google Patents
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellungInfo
- Publication number
- ATE454455T1 ATE454455T1 AT06719694T AT06719694T ATE454455T1 AT E454455 T1 ATE454455 T1 AT E454455T1 AT 06719694 T AT06719694 T AT 06719694T AT 06719694 T AT06719694 T AT 06719694T AT E454455 T1 ATE454455 T1 AT E454455T1
- Authority
- AT
- Austria
- Prior art keywords
- guiding
- production
- heterologous
- polypeptides
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64701305P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/002951 WO2006081430A2 (en) | 2005-01-27 | 2006-01-27 | Leader sequences for directing secretion of polypeptides and methods for production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454455T1 true ATE454455T1 (de) | 2010-01-15 |
Family
ID=36741080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06719694T ATE454455T1 (de) | 2005-01-27 | 2006-01-27 | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080286834A1 (de) |
| EP (1) | EP1841874B1 (de) |
| JP (2) | JP2008528033A (de) |
| AT (1) | ATE454455T1 (de) |
| AU (1) | AU2006207999A1 (de) |
| CA (1) | CA2589895A1 (de) |
| DE (1) | DE602006011574D1 (de) |
| DK (1) | DK1841874T3 (de) |
| WO (1) | WO2006081430A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006272759B2 (en) | 2005-07-22 | 2012-01-12 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| CA2621363C (en) * | 2005-09-13 | 2015-07-07 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2009056330A1 (en) * | 2007-10-31 | 2009-05-07 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| WO2009120810A2 (en) * | 2008-03-25 | 2009-10-01 | Cns Protein Therapeutics, Inc. | Neurodegenerative disorders |
| FR2933773B1 (fr) * | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| WO2010075194A1 (en) * | 2008-12-22 | 2010-07-01 | St. Jude Children's Research Hospital | Prokaryotic expression of soluble, active dkk |
| JP2010183885A (ja) * | 2009-02-13 | 2010-08-26 | Kobe Univ | タンパク質の製造方法およびそれに用いる発現ベクター |
| WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| DK2504363T3 (da) | 2009-11-24 | 2019-07-29 | Alethia Biotherapeutics Inc | Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| JP6008842B2 (ja) | 2010-05-04 | 2016-10-19 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｃｓｆ１ｒに結合する抗体 |
| US8431532B2 (en) | 2010-06-28 | 2013-04-30 | Five Prime Therepeutics, Inc. | FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same |
| EP2444495A1 (de) * | 2010-10-20 | 2012-04-25 | Algenics | Sekretion rekombinanter Polypeptide im extrazellularen Medium eines Diatoms |
| EP2640406A1 (de) | 2010-11-15 | 2013-09-25 | Five Prime Therapeutics, Inc. | Behandlung von krebs mit erhöhten dosen löslicher fgfr1-fusionsproteine |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| US20120183548A1 (en) | 2011-01-14 | 2012-07-19 | Five Prime Therapeutics, Inc. | IL-27 Antagonists for Treating Inflammatory Diseases |
| EP2780033B1 (de) | 2011-11-14 | 2019-05-08 | Five Prime Therapeutics, Inc. | Eine fgfr1 extrazelluläre domäne zur behandlung von krebs mit einer fgfr1 gen vervielfältigung |
| MX2014010164A (es) | 2012-02-22 | 2014-11-25 | Alethia Biotherapeutics Inc | Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer. |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| EP2929035A1 (de) | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidnanopartikel zur freisetzung von mrna |
| EP3431592A1 (de) | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Therapeutische mrna-zusammensetzungen und verwendung zur behandlung von krankheiten und störungen |
| HUE043815T2 (hu) | 2013-08-01 | 2019-09-30 | Five Prime Therapeutics Inc | Fukózmentes FGFR2IIIB elleni antitestek |
| KR20170016501A (ko) | 2014-06-23 | 2017-02-13 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| SG11201702723VA (en) | 2014-10-29 | 2017-05-30 | Five Prime Therapeutics Inc | Combination therapy for cancer |
| AU2015369854B2 (en) | 2014-12-22 | 2021-07-01 | Five Prime Therapeutics, Inc. | Anti-CSF1R antibodies for treating PVNS |
| EA037621B1 (ru) | 2015-03-23 | 2021-04-22 | Джаунс Терапьютикс, Инк. | Антитела к icos |
| MX2017013178A (es) | 2015-04-13 | 2018-03-01 | Five Prime Therapeutics Inc | Terapia de combinacion para cancer. |
| WO2017070423A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| WO2017187319A1 (en) | 2016-04-25 | 2017-11-02 | Glaxosmithkline Intellectual Property Development Limited | Nope for treatment of pathological muscle loss and weakness |
| WO2018085358A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
| CN109906030B (zh) | 2016-11-04 | 2022-03-18 | 安健基因公司 | 用于产生仅重链抗体的经基因修饰的非人动物和方法 |
| EP3562499A1 (de) * | 2016-12-29 | 2019-11-06 | Development Center for Biotechnology | Aus kininogen-1 abgeleitete peptide für proteinarzneimittel in vivo |
| CN110709420A (zh) | 2017-03-31 | 2020-01-17 | 戊瑞治疗有限公司 | 使用抗gitr抗体的癌症组合疗法 |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| WO2018226747A1 (en) | 2017-06-06 | 2018-12-13 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
| SG11202004806SA (en) | 2017-12-22 | 2020-06-29 | Jounce Therapeutics Inc | Antibodies to lilrb2 |
| EP3820904A2 (de) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | An ilt4 bindende antikörper |
| WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| EP4114931A4 (de) * | 2020-03-05 | 2024-05-01 | Curie Co. Inc. | Verfahren zur zellfreien proteinexpression von reifen polypeptiden aus zymogenen und proproteinen |
| AU2021325225A1 (en) | 2020-08-10 | 2023-03-23 | Gv20 Therapeutics Llc | Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8 |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
| DE1105508T1 (de) * | 1998-08-17 | 2002-02-21 | Europ Lab Molekularbiolog | Verfahren zur reinigung von proteinen und biomolekül- oder proteinkomplexen |
| US20080242603A1 (en) * | 2004-02-20 | 2008-10-02 | Yan Wang | Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use |
| US20070264277A1 (en) * | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
-
2006
- 2006-01-27 AT AT06719694T patent/ATE454455T1/de not_active IP Right Cessation
- 2006-01-27 AU AU2006207999A patent/AU2006207999A1/en not_active Abandoned
- 2006-01-27 DE DE602006011574T patent/DE602006011574D1/de active Active
- 2006-01-27 EP EP06719694A patent/EP1841874B1/de not_active Not-in-force
- 2006-01-27 JP JP2007553266A patent/JP2008528033A/ja active Pending
- 2006-01-27 WO PCT/US2006/002951 patent/WO2006081430A2/en active Application Filing
- 2006-01-27 DK DK06719694.9T patent/DK1841874T3/da active
- 2006-01-27 CA CA002589895A patent/CA2589895A1/en not_active Abandoned
- 2006-01-27 US US11/883,065 patent/US20080286834A1/en not_active Abandoned
-
2009
- 2009-01-19 JP JP2009009381A patent/JP2009131268A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1841874A2 (de) | 2007-10-10 |
| DE602006011574D1 (de) | 2010-02-25 |
| DK1841874T3 (da) | 2010-05-17 |
| EP1841874B1 (de) | 2010-01-06 |
| CA2589895A1 (en) | 2006-08-03 |
| WO2006081430A9 (en) | 2006-11-30 |
| JP2009131268A (ja) | 2009-06-18 |
| WO2006081430A2 (en) | 2006-08-03 |
| JP2008528033A (ja) | 2008-07-31 |
| AU2006207999A1 (en) | 2006-08-03 |
| US20080286834A1 (en) | 2008-11-20 |
| WO2006081430A3 (en) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454455T1 (de) | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung | |
| ATE478145T1 (de) | Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren | |
| ATE448246T1 (de) | Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung | |
| DE60137847D1 (de) | Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung | |
| WO2006053021A3 (en) | Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby | |
| CY1112334T1 (el) | Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων | |
| ATE408016T1 (de) | Verfahren zur herstellung und sekretion modifizierter peptide | |
| DK1609863T3 (da) | Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse | |
| ATE448312T1 (de) | Leitsequenzen zur verwendung bei der produktion von proteinen | |
| EP4302824A3 (de) | Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden | |
| DE60026733D1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
| DE60130804D1 (de) | Antagonistischer antikörper gegen pro842 | |
| ATE319858T1 (de) | Modulierte sekretierte alkalische phosphatase (seap) reporter gene und polypeptide | |
| DK1300417T3 (da) | Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor | |
| DE69926415D1 (de) | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren | |
| DK1591452T3 (da) | Secernerede og transmembrane polypeptider og nukleinsyrer kodende for samme | |
| DK1621619T3 (da) | Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse | |
| ATE447026T1 (de) | Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure | |
| DE69930422D1 (de) | Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |